Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Open Access
- 1 February 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 14 (2) , 326-342
Abstract
Most cancer therapies involve a component of treatment that inflicts DNA damage in tumor cells, such as double-strand breaks (DSBs), which are considered the most serious threat to genomic integrity. Complex systems have evolved to repair these lesions, and successful DSB repair is essential for tumor cell survival after exposure to ionizing radiation (IR) and other DNA-damaging agents. As such, inhibition of DNA repair is a potentially efficacious strategy for chemo- and radiosensitization. Homologous recombination (HR) and nonhomologous end-joining (NHEJ) represent the two major pathways by which DSBs are repaired in mammalian cells. Here, we report the design and execution of a high-throughput, cell-based small molecule screen for novel DSB repair inhibitors. We miniaturized our recently developed dual NHEJ and HR reporter system into a 384-well plate-based format and interrogated a diverse library of 20,000 compounds for molecules that selectively modulate NHEJ and HR repair in tumor cells. We identified a collection of novel hits that potently inhibit DSB repair, and we have validated their functional activity in a comprehensive panel of orthogonal secondary assays. A selection of these inhibitors was found to radiosensitize cancer cell lines in vitro, which suggests that they may be useful as novel chemo- and radio sensitizers. Surprisingly, we identified several FDA-approved drugs, including the calcium channel blocker mibefradil dihydrochloride, that demonstrated activity as DSB repair inhibitors and radiosensitizers. These findings suggest the possibility for repurposing them as tumor cell radiosensitizers in the future. Accordingly, we recently initiated a phase I clinical trial testing mibefradil as a glioma radiosensitizer. Mol Cancer Ther; 14(2); 326–42. ©2014 AACR.Keywords
All Related Versions
This publication has 82 references indexed in Scilit:
- Exploiting Synthetic Lethal Interactions Between DNA Damage Signaling, Checkpoint Control, and p53 for Targeted Cancer Therapy2012
- Assessing ‘radiosensitivity’ with kinetic profiles of γ-H2AX, 53BP1 and BRCA1 fociRadiotherapy and Oncology, 2011
- Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput ScreeningACS Chemical Biology, 2011
- Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repairNature, 2011
- Factors determining DNA double‐strand break repair pathway choice in G2 phaseThe EMBO Journal, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- Clinical Radiation Sensitivity With DNA Repair Disorders: An OverviewInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complexNature Chemical Biology, 2008
- Positional stability of single double-strand breaks in mammalian cellsNature Cell Biology, 2007